近日,东南大学附属中大医院副院长、放射科主任居胜红教授团队在权威期刊《Nano Today》(IF 17.4)发表了题为“Acidic Tumor Microenvironment-Activated MRI Nanoprobes for Modulation and Visualization of Anti-PD-L1 Immunotherapy”的研究成果。研究构建了一种新型pH响应性磁共振探针,探讨了pH调节对胰腺癌肿瘤免疫微环境...
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC. The results of clinical ...
2021年5月26日讯/生物谷/BIOON/---近日,澳门科技大学在Gut杂志上发表了题为"Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti- PD-1/PD- L1) immunotherapy"的研究性文章。
Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-specif...
CPI治疗中，高T/低髓系细胞浸润和B细胞丰度高分别在anti-PD-L1和anti-PD-1响应患者中富集。然而，这些特征作为预测性生物标记物的交叉验证产生了不一致的结果【2】，这可能是由于免疫肿瘤内异质性（ITH），尤其是因为先前的研究依赖于对单个肿瘤区域的评估。ITH是ccRCC的常见特征，与无定向扩散模式和术后结果相关...
原名:Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/ programmed cell death ligand1 (anti-PD- 1/PD-L1) immunotherapy 译名:人参多糖改变肠道菌群和犬尿氨酸/色氨酸比例,增强抗程序性细胞死亡1 /程序性细胞死...
2018年陈列平教授将靶向PD-1/PD-L1的治疗方式称为“Normalization Cancer immunotherapy”【1】,其主要原因是肿瘤微环境中的PD-L1是被诱导的,anti-PD-1/PD-L1能够使机体免疫系统恢复到正常的免疫稳态,因此,靶向PD-1/PD-L1的免疫治疗...
(29:39) Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase 1x 0:00 / 0:00 Subscribe to Podcast Key Points Question Is a universal cutoff value to define high tumor mutational burden (TMB) associated with tumor response to cancer immunotherapy?
9. Chen DS. Defining the Light at the End of the Tunnel: Biologic Problems and Engineering Solutions in Cancer Immunotherapy. AET2019. 10. Sharpe A. Discovery of New IO Targets and Mechanisms Leveraging CRISPR. SITC 2020. 11. Muik A, Altintas I, Kosoff R, Gieseke F, Schodel K, Salcedo...
总的来说,研究对转移性肾透明细胞癌在anti-PD-1治疗前和后的基因组和肿瘤免疫微环境的特征进行了详细的描绘,揭示出患者对anti-PD-1有响应的决定性因素,或对ccRCC病人的精准医疗具有参考价值。 原文链接: https://doi.org/10.1016/j.ccell.2021.10.001 ...